CrowdStrike Holdings Inc
Change company Symbol lookup
Select an option...
CRWD CrowdStrike Holdings Inc
CLABF Core One Labs Inc
FRHLF Freehold Royalties Ltd
WDAY Workday Inc
ENVX Enovix Corp
ENB Enbridge Inc
CHKP Check Point Software Technologies Ltd
NUSI Nationwide Nasdaq-100® Risk-Managed Income ETF
AMSF Amerisafe Inc
TNP-D Tsakos Energy Navigation Ltd
Go

Information Technology : Software | Large Cap Growth
Company profile

CrowdStrike Holdings, Inc. is a provider of cloud-delivered solutions for endpoint and cloud workload protection. The Company’s Falcon platform is comprised of two integrated technologies: lightweight agent and threat graph. The platform offers a set of cloud-delivered technologies that provides a wide range of products including antivirus, endpoint detection and response (EDR), device control, managed threat hunting, information technology (IT) hygiene, vulnerability management and threat intelligence. Its cloud modules include Falcon Horizon, Falcon Prevent, Falcon Device Control, Falcon Firewall Management, Falcon OverWatch, Falcon Discover, Falcon Complete, Falcon Spotlight, Falcon X, Falcon Search engine and Falcon Sandbox. Its Falcon Prevent provides antivirus capabilities to customers, delivering protection to defend customers against both malware and fileless attacks. Its Falcon Complete provides monitoring, management, response and remediation solution to its customers.

Closing Price
$176.70
Day's Change
1.80 (1.03%)
Bid
--
Ask
--
B/A Size
--
Day's High
181.50
Day's Low
172.17
Volume
(Average)
Volume:
4,674,749

10-day average volume:
4,948,195
4,674,749

SPPI LAWSUIT: The Law Offices of Vincent Wong Notify Investors of a Class Action Lawsuit Involving Spectrum Pharmaceuticals, Inc.

4:15 pm ET November 1, 2021 (Newsfile) Print

New York, New York--(Newsfile Corp. - November 1, 2021) - The Law Offices of Vincent Wong announce that a class action lawsuit has commenced in the on behalf of investors who purchased Spectrum Pharmaceuticals, Inc. ("Spectrum") (NASDAQ: SPPI) between December 27, 2018 and August 5, 2021.

If you suffered a loss, contact us at the link below. There is no cost or obligation to you.

https://www.wongesq.com/pslra-1/spectrum-pharmaceuticals-inc-loss-submission-form?prid=20813&wire=5

Cannot view this image? Visit: https://orders.newsfilecorp.com/files/7094/101602_570781_logo.jpg



Allegations against SPPI include that the Company made materially false and/or misleading statements and/or failed to disclose that: (i) the manufacturing facility for ROLONTIS, an investigational granulocyte-colony stimulating factor analog, maintained deficient controls and/or procedures; (ii) the foregoing deficiencies decreased the likelihood that the Food and Drug Administration would approve the ROLONTIS biologics license application ("BLA") in its current form; (iii) Spectrum had therefore materially overstated the ROLONTIS BLA's approval prospects; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.

If you suffered a loss in Spectrum you have until November 1, 2021 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

Vincent Wong, Esq.

39 East Broadway

Suite 304

New York, NY 10002

Tel. 212.425.1140

Fax. 866.699.3880

E-Mail: vw@wongesq.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/101602

comtex tracking

COMTEX_396196212/2523/2021-11-01T16:15:34

Earnings Calendar and Events Data provided by |Terms of Use| © 2022 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2022. All rights reserved.